Cochrane · systematic review · CD010705
GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs
Theron, G, Peter, J, Richardson, M, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
12
No studies
3
Included studies
NR
No studies 3 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 26.7%Moderate 6 · 40%High 2 · 13.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyMTBDRsl for FQ resistance, direct testing on smear‐positive specimens
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Test result | no estimate extracted | NR | No studies |
True positives (patients correctly diagnosed with FQ resistance) | no estimate extracted | 9 studies · 519 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
False negatives (patients incorrectly classified as not having FQ resistance) | no estimate extracted | 9 studies · 519 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
True negatives (patients correctly classified as not having FQ resistance) | no estimate extracted | 9 studies · 1252 participants | High |
False positives (patients incorrectly classified as having FQ resistance) | no estimate extracted | 9 studies · 1252 participants | High |
MTBDRsl for SLID resistance, direct testing on smear‐positive specimens
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Test result | no estimate extracted | NR | No studies |
True positives (patients correctly diagnosed with SLID resistance) | no estimate extracted | 8 studies · 348 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
False negatives (patients incorrectly classified as not having SLID resistance) | no estimate extracted | 8 studies · 348 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
True negatives (patients correctly classified as not having SLID resistance) | no estimate extracted | 8 studies · 1291 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
False positives (patients incorrectly classified as having SLID resistance) | no estimate extracted | 8 studies · 1291 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
MTBDRsl for XDR‐TB, direct testing on smear‐positive specimens
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Test result | no estimate extracted | NR | No studies |
True positives (patients correctly diagnosed with XDR‐TB) | no estimate extracted | 6 studies · 143 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
False negatives (patients incorrectly classified as not having XDR‐TB) | no estimate extracted | 6 studies · 143 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
True negatives (patients correctly classified as not having XDR‐TB) | no estimate extracted | 6 studies · 1277 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
False positives (patients incorrectly classified as having XDR‐TB) | no estimate extracted | 6 studies · 1277 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
MTBDRsl for fluoroquinolone resistance
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
12% | no estimate extracted | 16 studies · 1766 participants | Moderate Downgraded: indirectness |
17% | no estimate extracted | 16 studies · 1766 participants | Moderate Downgraded: indirectness |
21% | no estimate extracted | 16 studies · 1766 participants | Moderate Downgraded: indirectness |
Prevalence | no estimate extracted | NR | No studies |
MTBDRsl for second‐line drug resistance
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
15% | no estimate extracted | 14 studies · 1637 participants | Moderate Downgraded: imprecision, indirectness |
23% | no estimate extracted | 14 studies · 1637 participants | Moderate Downgraded: imprecision, indirectness |
30% | no estimate extracted | 14 studies · 1637 participants | Moderate Downgraded: imprecision, indirectness |
Prevalence | no estimate extracted | NR | No studies |
MTBDRsl for extensively drug‐resistant TB
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
8% | no estimate extracted | 8 studies · 880 participants | Low Downgraded: imprecision, indirectness |
11% | no estimate extracted | 8 studies · 880 participants | Low Downgraded: imprecision, indirectness |